Physician profile
Gautam Jayram
NPI 1265669683
$1,029,338.06
in general payments reported to CMS, 2019-2025
54 companies · $242K in 2025
The $242K reported for 2025 was more than what 99% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $100K · 2020: $78K · 2021: $101K · 2022: $144K · 2023: $211K · 2024: $153K · 2025: $242K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $310K · Consulting Fee: $202K · Travel and Lodging: $37K · Honoraria: $37K · Food and Beverage: $20K · Education: $61.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $310,005.50 |
| Consulting Fee | $202,206.86 |
| Travel and Lodging | $37,381.16 |
| Honoraria | $36,912.50 |
| Food and Beverage | $19,608.73 |
| Education | $61.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $303,393.69 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Sn Holdings, LLC | $157,653.52 | 2021-2024 | |
| Ferring Pharmaceuticals INC. | $138,215.06 | 2019-2025 | Adstiladrin, Menopur |
| Photocure INC | $84,568.92 | 2021-2025 | Cysview |
| E.R. Squibb & Sons, L.L.C. | $62,083.57 | 2021-2025 | Opdivo |
| Janssen Biotech, INC. | $53,836.35 | 2019-2025 | Carvykti, Rybrevant, Erleada |
| Astrazeneca Pharmaceuticals Lp | $41,575.67 | 2020-2025 | Imfinzi, Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $22,979.21 | 2019-2025 | |
| Urogpo LLC | $20,881.42 | 2019-2020 | |
| Urogen Pharma, INC. | $17,876.11 | 2021-2025 | Jelmyto |
| Immunitybio, INC. | $15,318.06 | 2025 | |
| Sun Pharmaceutical Industries INC. | $11,831.72 | 2022-2025 | Yonsa |
| Janssen Scientific Affairs, LLC | $10,817.63 | 2019-2025 | Erleada, Pipeline, Akeega |
| Intuitive Surgical, INC. | $10,607.61 | 2020-2021 | |
| Telix Pharmaceuticals | $10,109.38 | 2024-2025 | Illuccix |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $9,393.71 | 2019-2025 | |
| Karl Storz Endoscopy-America | $8,138.00 | 2025 | |
| Janssen Global Services, LLC | $7,933.84 | 2020-2025 | |
| Astellas Pharma US INC | $7,384.10 | 2019-2025 | Padcev, Xtandi, Myrbetriq |
| Tempus Ai, INC | $6,901.51 | 2024 | Xt Cdx |
| Emd Serono, INC. | $6,427.80 | 2019 | |
| Angiodynamics, INC. | $5,159.41 | 2021-2023 | Nanoknife |
| Amgen INC. | $5,032.67 | 2019-2025 | Xgeva |
| Blue Earth Diagnostics | $2,329.03 | 2019-2024 | |
| Astrazeneca Uk Limited | $2,148.00 | 2024 | |
| Dendreon Pharmaceuticals LLC | $1,466.05 | 2019-2025 | Provenge |
| Merck Kgaa | $1,035.00 | 2022 | |
| Janssen Research & Development, LLC | $817.50 | 2025 | |
| Janssen Pharmaceuticals, INC | $505.00 | 2021 | |
| Boston Scientific Corporation | $424.12 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $316.34 | 2023-2025 | Gemtesa, Orgovyx |
| Celgene Corporation | $300.00 | 2021 | |
| Exelixis INC. | $216.07 | 2021-2024 | Cabometyx |
| Abbvie INC. | $213.09 | 2023-2025 | |
| Progenics Pharmaceuticals, INC. | $163.77 | 2021-2025 | Pylarify |
| Endo Pharmaceuticals INC. | $148.12 | 2019-2021 | |
| Astellas Pharma Global Development | $141.54 | 2024 | Xtandi |
| Srs Medical Systems, INC. | $135.46 | 2020 | |
| Myovant Sciences INC. | $124.49 | 2021-2022 | |
| Accord Healthcare, INC. | $121.35 | 2023-2025 | |
| Verity Pharmaceuticals INC. | $118.96 | 2022-2025 | Trelstar, Tlando |
| Myriad Genetic Laboratories, INC. | $76.64 | 2021-2023 | Prolaris |
| Caris Mpi, INC. | $63.36 | 2025 | Mi Cancer Seek |
| Allergan, INC. | $58.37 | 2021-2022 | |
| Tolmar, INC. | $50.68 | 2023-2025 | Jatenzo, Eligard |
| Novartis Pharmaceuticals Corporation | $46.18 | 2022-2025 | |
| Aveo Pharmaceuticals, INC. | $38.96 | 2023 | Fotivda |
| Urovant Sciences INC | $33.20 | 2022 | |
| Baxter Healthcare | $31.94 | 2025 | Perclot |
| Laborie Medical Technologies Corp. | $27.62 | 2025 | |
| Procept Biorobotics Corporation | $26.98 | 2025 | |
| Eisai INC. | $23.81 | 2024 | |
| Genentech USA, INC. | $17.47 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$256,451.02 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gautam Jayram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.